Israeli startup CytoReason today announced a partnership with Swiss multinational, Ferring Pharmaceuticals, to establish new treatments for inflammatory bowel disease (IBD).
Read more here.
Israeli startup CytoReason today announced a partnership with Swiss multinational, Ferring Pharmaceuticals, to establish new treatments for inflammatory bowel disease (IBD).
Read more here.
![[Genesis in The Business Times] Genesis Alternative Ventures closes US$80m debt fund anchored by Sassoon family](https://blog.ourcrowd.com/wp-content/themes/Extra/images/post-format-thumb-text.svg)
